Zoetis Sustainability Profile
Zoetis Inc., headquartered in the United States, is a leading global animal health company dedicated to supporting the health and well-being of livestock and companion animals. Founded in 1952, Zoetis has established itself as a pioneer in the industry, focusing on the development of innovative vaccines, diagnostics, and therapeutics. With a strong presence in North America, Europe, and Asia, Zoetis offers a diverse portfolio of products that includes anti-infectives, parasiticides, and nutritional products. Their commitment to research and development has led to significant advancements in animal health, making them a trusted partner for veterinarians and farmers alike. Recognised for their market leadership, Zoetis continues to achieve notable milestones, reinforcing their position as a key player in the animal health sector.
DitchCarbon Score
How does Zoetis's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Zoetis's score of 31 is higher than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Zoetis's reported carbon emissions
In 2022, Zoetis reported total carbon emissions of approximately 303,186,000 kg CO2e, comprising 112,577,000 kg CO2e from Scope 1 emissions and 190,609,000 kg CO2e from Scope 2 emissions. This marked an increase from 2021, when their total emissions were about 288,208,000 kg CO2e, with Scope 1 emissions at 101,498,000 kg CO2e and Scope 2 emissions at 186,710,000 kg CO2e. In 2020, the total emissions were approximately 321,270,000 kg CO2e, indicating a downward trend in emissions over the past two years. Zoetis has set ambitious climate commitments, aiming to achieve carbon neutrality in its operations by 2030, specifically targeting Scope 1 and 2 emissions from manufacturing, research and development, office locations, and fleet vehicles. Additionally, the company plans to reduce energy intensity in its manufacturing and R&D processes by 5% by 2025, using 2019 as a baseline. These commitments reflect Zoetis's proactive approach to addressing climate change and reducing its carbon footprint within the veterinary pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | |
|---|---|---|---|
| Scope 1 | 77,694,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 243,576,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - |
How Carbon Intensive is Zoetis's Industry?
How Carbon Intensive is Zoetis's Location?
Zoetis's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Zoetis has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
